Form 4: Nuvectis Pharma Director James F. Oliviero III Acquires 30,000 Shares of Restricted Common Stock

Director James F. Oliviero III acquired 30,000 shares of restricted common stock in Nuvectis Pharma, Inc. on June 13, 2024.

Summary

• On June 13, 2024, James F. Oliviero III, a director of Nuvectis Pharma, Inc., acquired 30,000 shares of restricted common stock.
• The shares were acquired directly.
• Following the transaction, Oliviero directly owns 57,828 shares of common stock.
• The restricted common stock will vest in equal annual installments over three years, starting on the first anniversary of the grant date, contingent upon Oliviero's continued service on the board.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director is generally a positive sign, indicating confidence in the company's prospects. However, the impact is moderate as it's a relatively small transaction.

Positives

• The acquisition of shares by a director signals confidence in the company's future.

Future Outlook

The vesting of the restricted stock is contingent upon continued service on the board, incentivizing long-term commitment.

Industry Context

Acquisitions of company stock by directors are often viewed positively by the market, as they align the interests of management with those of shareholders.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates